- Home
- MYTE vs PRAX Comparison
MYTE vs PRAX Comparison
Compare MYTE & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYTE
- PRAX
- Stock Information
- Founded
- MYTE 2006
- PRAX 2015
- Country
- MYTE Germany
- PRAX United States
- Employees
- MYTE N/A
- PRAX N/A
- Industry
- MYTE Catalog/Specialty Distribution
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- MYTE Consumer Discretionary
- PRAX Health Care
- Exchange
- MYTE Nasdaq
- PRAX Nasdaq
- Market Cap
- MYTE 679.6M
- PRAX 599.7M
- IPO Year
- MYTE 2021
- PRAX 2020
- Fundamental
- Price
- MYTE $8.23
- PRAX $36.00
- Analyst Decision
- MYTE Hold
- PRAX Strong Buy
- Analyst Count
- MYTE 1
- PRAX 9
- Target Price
- MYTE $5.00
- PRAX $123.33
- AVG Volume (30 Days)
- MYTE 255.7K
- PRAX 569.3K
- Earning Date
- MYTE 05-14-2025
- PRAX 05-12-2025
- Dividend Yield
- MYTE N/A
- PRAX N/A
- EPS Growth
- MYTE N/A
- PRAX N/A
- EPS
- MYTE N/A
- PRAX N/A
- Revenue
- MYTE $912,559,271.00
- PRAX $8,553,000.00
- Revenue This Year
- MYTE $11.96
- PRAX N/A
- Revenue Next Year
- MYTE $10.37
- PRAX $789.73
- P/E Ratio
- MYTE N/A
- PRAX N/A
- Revenue Growth
- MYTE 12.41
- PRAX 249.53
- 52 Week Low
- MYTE $3.22
- PRAX $26.70
- 52 Week High
- MYTE $12.50
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- MYTE 53.50
- PRAX 48.79
- Support Level
- MYTE $7.27
- PRAX $28.79
- Resistance Level
- MYTE $8.24
- PRAX $37.97
- Average True Range (ATR)
- MYTE 0.50
- PRAX 2.66
- MACD
- MYTE 0.16
- PRAX 1.50
- Stochastic Oscillator
- MYTE 88.36
- PRAX 82.52
About MYTE MYT Netherlands Parent B.V. each representing one
MYT Netherlands Parent BV is a luxury e-commerce platform. The company offers luxury fashion wear for men, women, and kids. Also, the company sells shoes, bags, and accessories. The company operates in two segments which include the online segment and Retail store segments in which the majority of its revenue is generated from the Online segment.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.